Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction

28 May 2018 (16:07 - 16:13)

Organised by:

Abstract

Sign in to view the resources

About the speaker

Professor David Kaye

Baker Heart and Diabetes Institute, Melbourne (Australia)

6 More presentations in this session

Presentation thumbnail

Surfactant proteins changes after acute hemodynamic improvement in patients with advanced chronic heart failure treated with levosimendan

Doctor M. Mapelli (Milan, IT)

Abstract Slides

Presentation thumbnail

Stanford integrated psychosocial assessment for transplantation scores track with intermacs profile and predict readmissions in patients undergoing left ventricular assist device implantation

Doctor M. Cagliostro (New York, US)

Abstract Slides

Presentation thumbnail

What happened to patients being listed for Heart Transplantation who did not arrive to Transplantation? Reasons for coming out of the waiting list and long term follow-up

Doctor M. Castel Lavilla (Barcelona, ES)

Abstract Slides

Presentation thumbnail

Prognosis of patients with cardiac amyloidosis referred in the French national referral Centre for Cardiac Amyloidosis

Doctor D. Bodez (Creteil, FR)

Presentation thumbnail

Angiotensin based biomarkers predict outcome in HFpEF-patients

Doctor C. Binder (Vienna, AT)

Access the full session

Session thumbnail

Moderated Poster session 5 - Advanced heart failure

The Event

Heart Failure 2018

28 May 2018 16:07 CET

You may be interested in

Congress Session

Clinical phenotypes of heart failure with preserved ejection fraction

Webinar

Advanced heart failure therapy in HF patients with preserved and mildly reduced ejection fraction

Webinar

Acute heart failure in patients with preserved ejection fraction (AHFPEF)

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources